GenomOncology

GenomOncology develops precision oncology solutions that enhance cancer care by leveraging data-driven insights to interpret genomic information effectively. GenomOncology focuses on providing precision oncology solutions that enhance cancer care through advanced data interpretation. The company is headquartered in Cleveland, US. The CEO, Bradley Wertz, has led the company since its establishment.

In February 2014, GenomOncology raised USD 250,000 from investor JumpStart during its latest funding round, which is part of their overall capital raised of USD 250,000. The company has completed a total of 4 deals. GenomOncology specializes in precision oncology solutions designed to improve cancer care through data-driven insights. At the heart of their offerings is the Precision Oncology Platform (POP), which integrates proprietary algorithms and machine learning techniques to transform complex genomic and clinical data into actionable insights.

This platform facilitates the seamless processing of genetic test results, providing clinicians with validated, interpretive insights for both somatic and hereditary tests. Additionally, GenomOncology offers data enablement solutions such as igniteIQ, which extracts clinically relevant data from unstructured documents, and GO Connect, which enables genomic data interoperability across various client applications. Their products cater to a diverse clientele, including leading healthcare institutions, nationally recognized molecular labs, and NCI/NCCN designated providers primarily in North America and Europe, focusing on enhancing precision oncology workflows and integrating seamlessly into existing clinical practices. GenomOncology generates revenue through a combination of subscription-based services and partnerships with healthcare institutions and labs.

Their flagship offerings, including the Precision Oncology Platform and the GO Pathology Workbench, are typically sold under multi-year contracts that allow clients to access their suite of software solutions. Transactions are structured as B2B agreements, where organizations pay for licenses and ongoing support, facilitating continuous updates and enhancements to the software. The pricing plans are tiered based on the scale of usage and the specific needs of the client, fostering a scalable approach to adoption and integration within diverse healthcare environments. These structured transactions ensure that GenomOncology aligns its solutions with the evolving needs of precision oncology, thereby driving both customer satisfaction and retention.

GenomOncology aims to enhance its product offerings by developing new features within the Precision Oncology Platform and expanding its capabilities in genomic data analysis. The company is also looking to enter new markets, specifically targeting Europe and additional regions in North America by 2015. The recent funding raised in February 2014 will support these initiatives, allowing GenomOncology to invest in technology development and market expansion efforts.